XML 116 R38.htm IDEA: XBRL DOCUMENT
v3.20.1

Restructuring, Impairment and Related Charges (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2020
Restructuring and Related Activities [Abstract] |
Summary of details for charges recorded | Restructuring, impairment and related charges for the Company’s fiscal 2019 initiatives for the year ended March 31, 2020 consisted of the following:
| Year Ended March 31, 2020
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 3 |  |  | $ | 1 |  |  | $ | 2 |  |  | $ | 1 |  |  | $ | 33 |  |  | $ | 40 |
Exit and other-related costs (1) | — |  |  | 11 |  |  | 19 |  |  | 1 |  |  | 44 |  |  | 75 |
Asset impairments and accelerated depreciation | — |  |  | 5 |  |  | 1 |  |  | — |  |  | 10 |  |  | 16 |
Total | $ | 3 |  |  | $ | 17 |  |  | $ | 22 |  |  | $ | 2 |  |  | $ | 87 |  |  | $ | 131 |
(1) | Exit and other-related costs primarily include project consulting fees.
Restructuring, impairment and related charges for the Company’s fiscal 2019 initiatives for the year ended March 31, 2019 consisted of the following:
| Year Ended March 31, 2019
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 50 |  |  | $ | 33 |  |  | $ | 19 |  |  | $ | 16 |  |  | $ | 36 |  |  | $ | 154 |
Exit and other-related costs (1) | 7 |  |  | 3 |  |  | 20 |  |  | 57 |  |  | 57 |  |  | 144 |
Asset impairments and accelerated depreciation | 6 |  |  | 5 |  |  | 3 |  |  | 18 |  |  | 1 |  |  | 33 |
Total | $ | 63 |  |  | $ | 41 |  |  | $ | 42 |  |  | $ | 91 |  |  | $ | 94 |  |  | $ | 331 |
(1) | Exit and other-related costs primarily include lease and other contract exit costs associated with closures of facilities and retail pharmacy stores as well as project consulting fees.
The following table summarizes the activity related to the restructuring liabilities associated with the fiscal 2019 initiatives for the year ended March 31, 2020:
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Corporate |  | Total
Balance, March 31, 2019 (1) | $ | 31 |  |  | $ | 38 |  |  | $ | 15 |  |  | $ | 29 |  |  | $ | 37 |  |  | $ | 150 |
Restructuring charges recognized | 3 |  |  | 17 |  |  | 22 |  |  | 2 |  |  | 87 |  |  | 131 |
Non-cash charges | — |  |  | (5 | ) |  | (1 | ) |  | — |  |  | (10 | ) |  | (16 | )
Cash payments | (13 | ) |  | (26 | ) |  | (16 | ) |  | (20 | ) |  | (61 | ) |  | (136 | )
Other | 1 |  |  | — |  |  | (2 | ) |  | (4 | ) |  | (14 | ) |  | (19 | )
Balance, March 31, 2020 (2) | $ | 22 |  |  | $ | 24 |  |  | $ | 18 |  |  | $ | 7 |  |  | $ | 39 |  |  | $ | 110 |
(1) | As of March 31, 2019, the total reserve balance was $150 million of which $117 million was recorded in other accrued liabilities and $33 million was recorded in other noncurrent liabilities.
(2) | As of March 31, 2020, the total reserve balance was $110 million of which $99 million was recorded in other accrued liabilities and $11 million was recorded in other noncurrent liabilities.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration